132
Views
4
CrossRef citations to date
0
Altmetric
Review Articles

Duration of dual anti-platelet therapy – State of the art after the DAPT and PEGASUS-TIMI 54 trials

, MD, , MD, PhD, , MD, , MD, PhD & , MD, PhD
Pages 256-264 | Received 14 Apr 2016, Accepted 16 Jun 2016, Published online: 21 Mar 2017
 

Abstract

Dual anti-platelet therapy is prescribed in the setting of coronary heart disease for the prevention of stent thrombosis and acute thrombotic events. The optimal duration of dual anti-platelet therapy is still under debate as numerous trials have shown non-inferiority of a strategy of early cessation of one of the agents as compared to the standard practice whereas two larger trials have demonstrated benefit of prolonging dual anti-platelet therapy.

CONFLICT OF INTEREST

none.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.